Deprecated: Creation of dynamic property Permalink_Manager_Class::$permalink_manager_uris is deprecated in /var/www/contraception-esc.com/wp-content/plugins/permalink-manager-pro/permalink-manager.php on line 137

Deprecated: Creation of dynamic property Permalink_Manager_Class::$permalink_manager_permastructs is deprecated in /var/www/contraception-esc.com/wp-content/plugins/permalink-manager-pro/permalink-manager.php on line 138

Deprecated: Creation of dynamic property Permalink_Manager_Class::$permalink_manager_redirects is deprecated in /var/www/contraception-esc.com/wp-content/plugins/permalink-manager-pro/permalink-manager.php on line 139

Deprecated: Creation of dynamic property Permalink_Manager_Class::$permalink_manager_external_redirects is deprecated in /var/www/contraception-esc.com/wp-content/plugins/permalink-manager-pro/permalink-manager.php on line 140

Deprecated: Creation of dynamic property Permalink_Manager_Class::$permalink_manager_alerts is deprecated in /var/www/contraception-esc.com/wp-content/plugins/permalink-manager-pro/permalink-manager.php on line 145
Clinical experience with NuvaRing® in Spain shows that the monthly contraceptive ring is associated with a low incidence of hormone-related adverse effects - contraception-esc.com

Clinical experience with NuvaRing® in Spain shows that the monthly contraceptive ring is associated with a low incidence of hormone-related adverse effects

Clinical experience with NuvaRing® in Spain shows that the

monthly contraceptive ring is associated with a low incidence of hormone-related

adverse effects 

I Lete 

Lasa Santiago Apóstol Hospital, Gynecology Department,

Vitoria, Spain 

Background The adverse effects most commonly reported during the

use of combined oral contraceptives (COCs) are nausea, headache and mastalgia.

Although a precise evaluation is complex, the incidence of these adverse effects

seems to be associated, at least partially, with the estrogen component of COCs. 

Objective To evaluate the adverse effects associated with the use of

contraceptive hormones in users of the monthly contraceptive ring, NuvaRing®. 

Methods A total of 896 Spanish women attending their normal centre-family

planning centre, hospital or private centre-to request contraceptive advice were

invited to participate in this observational, multicentre, prospective, open

study. Evaluations were carried out at baseline, and after three and six cycles

of ring use. NuvaRing® users were classified as either new users of hormonal

contraception (HC) or switchers-those switching from another HC method to the

monthly contraceptive ring. To evaluate the reduction in hormone-related adverse

effects, only the women who had switched from another HC method were assessed

for specific effects compared with baseline (their previous method). 

Results Of

the total group of 805 women (mean age = 29 ± 6 years) who started using

NuvaRing®, 722 (90%) completed cycle 3 and 595 (74%) completed cycle 6. For

switchers (47.5% of the total group), the incidence of nausea, headache and

mastalgia was significantly lower after 3 cycles of ring use and this

improvement was maintained and strengthened after 6 cycles. More specifically,

the percentage of women who had breast hypersensitivity decreased from 6.4% at

baseline to 1.7% after 6 cycles of use (p<0.05). Headache also decreased, from 10% of women at baseline to 1.2% after 6 cycles (p<0.01). Although the percentage of women reporting nausea was already low at the start of the study (4.8%), this too fell significantly, to 0.4% after 6 cycles of ring use (p<0.05). 

Conclusions The low incidence of hormone-related adverse effects

with the monthly contraceptive ring can be attributed to the ring’s low and

steady release of hormones.

Scroll to Top